Dual effects of bisphosphonates on ectopic skin and vascular soft tissue mineralization versus bone microarchitecture in a mouse model of generalized arterial calcification of infancy

Journal of Investigative Dermatology

Volumn 136, Issue 1, 2016, Pages 275-283

  Li, Qiaoli ^a   Kingman, Joshua ^a   Sundberg, John P ^b   Levine, Michael A ^c   Uitto, Jouni ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b JACKSON LABORATORY   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ETIDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CALCIFICATION; ARTICLE; ASSAY; BONE MICROARCHITECTURE; BONE MINERALIZATION; BONE STRUCTURE; CALCIUM ASSAY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; ECTOPIC SKIN MINERALIZATION; FEMALE; GENERALIZED ARTERIAL CALCIFICATION; IN VITRO STUDY; INFANT; INFANT DISEASE; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE METABOLISM; VASCULAR SOFT TISSUE MINERALIZATION; VASCULAR TISSUE; ANIMAL; BONE; C57BL MOUSE; CHORISTOMA; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; MUTANT MOUSE STRAIN; NEEDLE BIOPSY; NEWBORN; PATHOLOGY; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; SKIN; VASCULAR CALCIFICATION;

ANIMALS; ANIMALS, NEWBORN; BIOPSY, NEEDLE; BONE AND BONES; CHORISTOMA; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; ETIDRONIC ACID; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; SKIN; VASCULAR CALCIFICATION; X-RAY MICROTOMOGRAPHY;

EID: 84959525365     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/JID.2015.377     Document Type: Article

References (34)

1. Bouleftour W, Boudiffa M, Wade-Gueye NM, et al. Skeletal development of mice lacking bone sialoprotein (BSP)-impairment of long bone growth and progressive establishment of high trabecular bone mass. PLoS One 2014;9:e95144.
2. Chong CR, Hutchins GM. Idiopathic infantile arterial calcification: the spectrum of clinical presentations. Pediatr Dev Pathol 2008;11:405-15.
3. Edouard T, Chabot G, Miro J, et al. Efficacy and safety of 2-year etidronate treatment in a child with generalized arterial calcification of infancy. Eur J Pediatr 2011;170:1585-90.
4. Francis MD, Valent DJ. Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases. J Musculoskelet Neuronal Interact 2007;7:2-8.
5. Galletti S, Nitschke Y, Malavolti AM, et al. Generalized arterial calcification of infancy: fatal clinical course associated with a novel mutation in ENPP1. JIMD Rep 2011;1:23-7.
6. Hajjawi MO, MacRae VE, Huesa C, et al. Mineralisation of collagen rich soft tissues and osteocyte lacunae in Enpp1(e/e) mice. Bone 2014;69: 139-47.
7. Jansen RS, Duijst S, Mahakena S, et al. ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol 2014;34:1985-9.
8. Jansen RS, Kucukosmanoglu A, de Haas M, et al. ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci USA 2013;110:20206-11.
9. Kavukcuoglu NB, Li Q, Pleshko N, et al. Connective tissue mineralization in Abcc6(e/e) mice, a model for pseudoxanthoma elasticum. Matrix Biol 2012;31:246-52.
10. LaRusso J, Li Q, Jiang Q, et al. Elevated dietary magnesium prevents connective tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6e/e). J Invest Dermatol 2009;129:1388-94.
11. Li Q, Brodsky JL, Conlin L, et al. Mutations in the ABCC6 gene as a cause of generalized arterial calcification of infancy: genotypic overlap with pseudoxanthoma elasticum. J Invest Dermatol 2014;134:658-65.
12. Li Q, Guo H, Chou DW, et al. Mutant Enpp1asj mouse as a model for generalized arterial calcification of infancy. Dis Model Mech 2013;6: 1227-35.
13. Li Q, LaRusso J, Grand-Pierre AE, et al. Magnesium carbonate-containing phosphate binder prevents connective tissue mineralization in Abcc6e/e mice-potential for treatment of pseudoxanthoma elasticum. Clin Transl Sci 2009;2:398-404.
14. Li Q, Schumacher W, Siegel D, et al. Cutaneous features of pseudoxanthoma elasticum in a patient with generalized arterial calcification of infancy due to a homozygous missense mutation in the ENPP1 gene. Br J Dermatol 2012;166:1107-11.
15. Li Q, Uitto J. Mineralization/anti-mineralization networks in the skin and vascular connective tissues. Am J Pathol 2013;183:10-8.
16. Lorenz-Depiereux B, Schnabel D, Tiosano D, et al. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 2010;86: 267-72.
17. Mackenzie NC, Zhu D, Milne EM, et al. Altered bone development and an increase in FGF-23 expression in Enpp1e/e mice. PLoS One 2012;7: e32177.
18. Nitschke Y, Baujat G, Botschen U, et al. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. Am J Hum Genet 2012;90:25-39.
19. Nitschke Y, Rutsch F. Generalized arterial calcification of infancy and pseudoxanthoma elasticum: two sides of the same coin. Front Genet 2012a;3: 302.
20. Nitschke Y, Rutsch F. Genetics in arterial calcification: lessons learned from rare diseases. Trends Cardiovasc Med 2012b;22:145-9.
21. O'Neill WC, Lomashvili KA, Malluche HH, et al. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 2011;79: 512-7.
22. Otero JE, Gottesman GS, McAlister WH, et al. Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy. J Bone Miner Res 2013;28:419-30.
23. Pennypacker B, Shea M, Liu Q, et al. Bone density, strength, and formation in adult cathepsin K (e/e) mice. Bone 2009;44:199-207.
24. Ramjan KA, Roscioli T, Rutsch F, et al. Generalized arterial calcification of infancy: treatment with bisphosphonates. Nat Clin Pract Endocrinol Metab 2009;5:167-72.
25. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996;97:2692-6.
26. Ruf N, Uhlenberg B, Terkeltaub R, et al. The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). Hum Mutat 2005;25:98.
27. Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006;1068:367-401.
28. Rutsch F, Boyer P, Nitschke Y, et al. Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet 2008;1:133-40.
29. Rutsch F, Nitschke Y, Terkeltaub R. Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. Circ Res 2011;109:578-92.
30. Rutsch F, Ruf N, Vaingankar S, et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003;34: 379-81.
31. Silverman SL, Hurvitz EA, Nelson VS, et al. Rachitic syndrome after disodium etidronate therapy in an adolescent. Arch Phys Med Rehabil 1994;75: 118-20.
32. Thomas T, Lafage MH, Alexandre C. Atypical osteomalacia after 2 year etidronate intermittent cyclic administration in osteoporosis. J Rheumatol 1995;22:2183-5.
33. Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 2002;8:1929-44.
34. Uveges TE, Kozloff KM, Ty JM, et al. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J Bone Miner Res 2009;24:849-59.